NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP
24.2.2026 14:00:00 CET | Business Wire | Press Release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/
Supporting stable, high-titer cell line development and seamless GMP advancement.
The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and regulatory quality. Together, the companies offer an integrated model that minimizes tech-transfer delays, reduces the risk of costly cell line rebuilds, and accelerates the path to IND-enabling and clinical material.
A Partnership Designed to Reduce Risk and Gain Time
The joint offering addresses some of the most common challenges faced by biotech companies: long development cycles, technical bottlenecks, and costly delays that impact valuation and fundraising timelines. By streamlining CLD and GMP manufacturing, customers gain a clear, uninterrupted path from early development to high-quality material suitable for clinical studies. For early-stage biotech companies operating against tight funding timelines, even a three-month delay can materially impact valuation and financing outcomes.
“Partnering with Demeetra strengthens our ability to support biotech companies all the way, with a rapid, reliable, and continuous path to GMP material,” said Janet Hoogstraate, CEO of NorthX Biologics. “Biotech companies no longer need to choose between best-in-class cell line development and proven GMP execution. Our collaboration with Demeetra provides an optimal solution for development of biologics.”
“We are excited to collaborate with NorthX Biologics,” said Jack Crawford, CEO of Demeetra. “Demeetra's platforms are designed to produce cell lines that go straight into manufacturing without rebuilds or licensing conversations downstream. Partnering with NorthX Biologics closes the loop. Together we've built a high-performance, end-to-end path that protects both the program timeline and the full economic value of the client’s asset.”
Key Customer Benefits
- Royalty-free cell line development – molecule retains full economic value through fundraising, partnering or acquisition
- A single, coordinated team – direct transition from CLD to GMP manufacturing with no re-qualification
- Reduced technical and regulatory risk
- Shorter timelines to IND/Phase I
The Demeetra and NorthX Biologics collaboration reflects a shared commitment to reducing fragmentation in early biologics development. By integrating genome engineering, cell line development, upstream processing, and GMP execution within a coordinated framework, the companies aim to simplify decision-making for biotech leaders and reduce the cumulative risk associated with multi-vendor handoffs.
About NorthX Biologics
NorthX Biologics is a leading contract development and manufacturing organization (CDMO) and Sweden’s national innovation hub for advanced biologics, enabling next-generation therapies beyond traditional manufacturing. With over 30 years of GMP experience, NorthX Biologics offers end-to-end services including process development, recombinant proteins, vaccines, viral vectors, cell therapies, and aseptic fill & finish. With its headquarters in Matfors, Sweden, and a facility in Stockholm, NorthX Biologics serves customers worldwide.
About Demeetra
Demeetra is a genome engineering company providing integrated platforms for gene editing, transposon-based integration, and cell line development. Demeetra’s technologies deliver high performance with clear intellectual property lineage, enabling confident adoption across research, development, and biomanufacturing workflows.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224427714/en/
Contacts
Janet Hoogstraate
Chief Executive Officer
Email: janet.hoogstraate@nxbio.com
Website: www.nxbio.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nxbio.com&e
sheet=54431808&newsitemid=20260224427714&lan=en-US&anchor=www.nxbio.com&index=4&
md5=87e1b4396b580df9f924192de9815376
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press Release
Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press Release
Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press Release
Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press Release
NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press Release
Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redundant Command and Data Handling systems as well as the Instrument Command and Data Handling systems for both the Wide Field Instrument and Coronagraph Instrum
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom